Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2CLIMB: tucatinib vs placebo with capecitabine and trastuzumab in previously treated HER2-positive advanced or metastatic breast cancer
MOH_2017-10-16_000862Phase 2Not yet recruiting
- Sponsor
- Pfizer
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Tucatinib + capecitabine + trastuzumab with Placebo + capecitabine + trastuzumab (2 arms). Planned start Aug 2017; status: not yet recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2017-10-16_000862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-10-16_000862.